Despite improvements in cancer therapies, metastatic solid cancers remain largely incurable. The discovery of ER+ and HER2+ as therapeutic targets in breast cancer (BC) has enabled treatment success with blocking therapies. On the other hand, metastatic triple-negative BC (ER-/PR-/HER2-) is an aggressive subtype of BC marked by poor survival. No therapy exists and therefore patients have an unmet medical need. Finding alternative strategies are a requirement in cancer treatment and patient welfare. Accumulating knowledge indicate a prominent role for long noncoding RNAs (lncRNAs) in cancer cell survival, growth and metastatic potential. LncRNAs are a heterogeneous group of non-coding transcripts that regulate gene expression through diverse mechanisms. Our preliminary results demonstrate that lncRNAs can be manipulated with biomedical applications. These findings have raised the likelihood that lncRNAs represent an unexploited reservoir of potential therapeutic targets for BC.